Danirixin
Idiopathic Pulmonary Fibrosis
Clinical trials
1
Developer
GlaxoSmithKline
Overview
Danirixin is an agent tracked by PF-Atlas in the context of idiopathic pulmonary fibrosis. It appears in 1 tracked IPF clinical trial.
Danirixin clinical trials
Explore related
Medical disclaimer. This page summarizes research about Danirixin for information only. It is not medical advice. Verify approval status and evidence with the FDA and a pulmonologist.